Onkologie. 2018:12(3):117-122 | DOI: 10.36290/xon.2018.023

Role of the hematologist in the multidisciplinary care for patients with cutaneous lymphomas

Jindřich Polívka1, Jiří Ettler2
1 I. interní klinika – hematologie, 1. LF UK a Všeobecná fakultní nemocnice v Praze
2 Dermatovenerologická klinika, 3. LF UK a Fakultní nemocnice Královské Vinohrady v Praze

Primary cutaneous lymphomas form a heterogeneous group of rare hematologic malignancies. A multidisciplinary approachis essential for the management of patients with cutaneous lymphoma. The aims to present the role of the hematologist in themultidisciplinary care for patients with cutaneous lymphomas in the Czech Republic. It focuses on current best practices in thediagnosis and treatment of primary cutaneous lymphomas.

Keywords: hematology/oncology, dermatology, cutaneous lymphomas, mycosis fungoides, Sézary syndrome

Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polívka J, Ettler J. Role of the hematologist in the multidisciplinary care for patients with cutaneous lymphomas. Onkologie. 2018;12(3):117-122. doi: 10.36290/xon.2018.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Polivka J, Muzik J. Epidemiology of primary cutaneous lymphomas in the Czech Republic according to data of the Czech National Cancer Registry. předneseno na Cutaneous Lymphomas: Insight & Therapeutic Progress, 13-15 October 2017, London.
    2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390. Go to original source... Go to PubMed...
    3. Mitteldorf C, Grabbe S, Stadler R. WHO-Klassifikation und klinisches Spektrum der kutanen LymphomeWHO classification and clinical spectrum of cutaneous lymphomas. Hautarzt 2017; 68(9): 682-695. Go to original source... Go to PubMed...
    4. Cerroni L. Past, present and future of cutaneous lymphomas. Semin Diagn Pathol. 2017; 34(1): 3-14. Go to original source... Go to PubMed...
    5. Rubio - Gonzalez B, Zain J, Rosen ST, et al. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol. 2017; 176(1): 16-36. Go to original source... Go to PubMed...
    6. Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol. 2015; 90(5): 687-706. Go to original source... Go to PubMed...
    7. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia. 2010; 24(1): 13-21. Go to original source... Go to PubMed...
    8. Olsen EA. Evaluation, Diagnosis, and Staging of cutaneous Lymphoma. Dermatol Clin. 2015; 33: 643-654. Go to original source... Go to PubMed...
    9. Vidulich KA, Talpur R, Bassett RL, et al. Overall survival in erythrodermic cutaneous T - cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T - cell lymphoma. Int J Dermatol. 2009; 48(3): 243-252. Go to original source... Go to PubMed...
    10. Magro CM, Crowson AN, Mihm MC. The cutaneous lymphoid proliferations: a comprehensive textbook of lymphocytic infiltrates of the skin. John Wiley & Sons 2016: 568 s. Go to original source...
    11. Olsen EA, Vonderheid E, Pimpinelli N, et al. Revisions of the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 1713-1722. Go to original source... Go to PubMed...
    12. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Se'zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011; 29: 2598-2607. Go to original source... Go to PubMed...
    13. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 479-484. Go to original source... Go to PubMed...
    14. Dippel E, Assaf C, Becker JC, et al. S2k Guidelines-Cutaneous Lymphomas Update 2016-Part 1: Classification and Diagnosis (ICD10 C82-C86). J Dtsch Dermatol Ges. 2017; 15(12): 1266-1273. Go to original source... Go to PubMed...
    15. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017; 77: 57-74. Go to original source... Go to PubMed...
    16. Dippel E, Assaf C, Becker JC, et al. S2k Guidelines-Cutaneous Lymphomas Update 2016-Part 2: Treatment and Follow-up (ICD10 C82-C86). J Dtsch Dermatol Ges. 2018; 16(1): 112-122. Go to original source... Go to PubMed...
    17. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118(15): 4024-4035. Go to original source... Go to PubMed...
    18. Wieser I, Tetzlaff MT, Torres Cabala CA, et al. Primary cutaneous CD30+ lymphoproliferative disorders. J Dtsch Dermatol Ges. 2016; 14(8): 767-782. Go to original source... Go to PubMed...
    19. Nicolay JP, Wobser M. Cutaneous B-cell lymphomas-pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges. 2016; 14(12): 1207-1224. Go to original source... Go to PubMed...
    20. Suárez AL, Querfeld C, Horwitz S, et al. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. J Am Acad Dermatol. 2013; 69(3): 343.e1-1. Go to original source... Go to PubMed...
    21. Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?. Br J Dermatol. 2014; 170(6): 1226-1236. Go to original source... Go to PubMed...
    22. Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017; 92(10): 1085-1102. Go to original source... Go to PubMed...
    23. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010; 28(31): 4730-4739. Go to original source... Go to PubMed...
    24. Scarisbrick J, Prince H, Vermeer M, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015; 33(32): 3766-3773. Go to original source... Go to PubMed...
    25. Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. ASH Education Program Book, 2015; 2015(1): 529-544. Go to original source... Go to PubMed...
    26. Woo, DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009; 145(6): 667-674. Go to original source... Go to PubMed...
    27. Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol. 2011; 90: 401-408. Go to original source... Go to PubMed...
    28. Selva RL, Violetti SA, Delfino C, et al. A literature revision in primary cutaneous B-cell lymphoma. Indian J Dermatol. 2017; 62: 146-157. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.